BLOG

BLOG

2021-07-20

Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines

SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platforms.
More +

2021-07-19

Junshi Biosciences and Immorna announced that they will establish a joint venture.

SHANGHAI, July 19, 2021 /PRNewswire/ — Junshi Biosciences (1877.HK, 688180.SH), a biopharmaceutical company driven by innovation and dedicated to the discovery, development, and commercialization of innovative therapies, and Jia Chen Xi Hai, a cutting-edge biotechnology company focused on the optimization of mRNA and delivery vector technologies as well as the research and development of novel nucleic acid-based drugs, today announced that they have entered into a strategic cooperation agreement. Under the agreement, the two companies will jointly establish a joint venture to collaborate globally on the development and commercialization of new drug candidates targeting diseases such as cancer, infectious diseases, and rare diseases, leveraging the mRNA technology platform and other advanced technology platforms.
More +

2021-07-19

China’s Kangtai Biological Partners With Startup to Develop mRNA Vaccines

(Yicai Global) July 19 -- Leading Chinese vaccine developer Kangtai Biological Products said it plans to work with a biotech startup to develop shots based on mRNA technology.
More +

2021-07-09

I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms

SHANGHAI and GAITHERSBURG, Md., July 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the signing of two new collaborations with emerging biotech companies in China to strengthen its next-generation innovation pipeline.
More +
< 123 >

Business license

Statement

SEO